DK0809700T3 - Papillomaviruslignende partikler, fusionsproteiner samt fremgangsmåde til fremstilling heraf - Google Patents
Papillomaviruslignende partikler, fusionsproteiner samt fremgangsmåde til fremstilling herafInfo
- Publication number
- DK0809700T3 DK0809700T3 DK95934663T DK95934663T DK0809700T3 DK 0809700 T3 DK0809700 T3 DK 0809700T3 DK 95934663 T DK95934663 T DK 95934663T DK 95934663 T DK95934663 T DK 95934663T DK 0809700 T3 DK0809700 T3 DK 0809700T3
- Authority
- DK
- Denmark
- Prior art keywords
- particles
- proteins
- deleted
- fusion proteins
- vlp
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19944435907 DE4435907C2 (de) | 1994-10-07 | 1994-10-07 | Papillomavirusähnliche Partikel und deren Anwendung |
DE1995126752 DE19526752C2 (de) | 1995-07-21 | 1995-07-21 | Hocheffiziente Bildung von Papillomavirusähnlichen Partikeln |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0809700T3 true DK0809700T3 (da) | 2006-09-18 |
Family
ID=25940851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK95934663T DK0809700T3 (da) | 1994-10-07 | 1995-10-09 | Papillomaviruslignende partikler, fusionsproteiner samt fremgangsmåde til fremstilling heraf |
Country Status (13)
Country | Link |
---|---|
US (6) | US6066324A (nl) |
EP (2) | EP1728800A1 (nl) |
JP (6) | JPH11504801A (nl) |
AT (1) | ATE325875T1 (nl) |
AU (2) | AU4270196A (nl) |
CA (1) | CA2202090C (nl) |
DE (3) | DE122007000092I1 (nl) |
DK (1) | DK0809700T3 (nl) |
ES (1) | ES2264563T3 (nl) |
LU (2) | LU91401I2 (nl) |
NL (2) | NL300323I2 (nl) |
PT (1) | PT809700E (nl) |
WO (1) | WO1996011272A2 (nl) |
Families Citing this family (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020164350A1 (en) | 1992-09-03 | 2002-11-07 | Lowy Douglas R. | Chimeric papillomavirus-like particles |
US8062642B1 (en) | 1993-03-09 | 2011-11-22 | University Of Rochester | Production of papillomavirus capsid protein and virus-like particles |
CA2202090C (en) * | 1994-10-07 | 2012-04-17 | Lutz Gissmann | Papilloma virus-like particles, fusion proteins as well as processes for their production |
EP0922105B1 (en) * | 1996-07-17 | 2005-12-07 | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Infectious papillomavirus pseudoviral particles |
DE19631357A1 (de) * | 1996-08-02 | 1998-02-05 | Deutsches Krebsforsch | Vektor zur Aktivierung des Immunsystems gegen mit Papillomviren bzw. Sequenzen davon assoziierten Zellen |
GB9621091D0 (en) | 1996-10-09 | 1996-11-27 | Fondation Pour Le Perfectionem | Attenuated microorganisms strains and their uses |
ATE341339T1 (de) * | 1996-12-20 | 2006-10-15 | Merck & Co Inc | Zusammensetzungen von rekombinanten papillomavirus vakzinen |
AU755679B2 (en) * | 1997-07-03 | 2002-12-19 | Medimmune, Llc | Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture,and the use thereof as diagnostic, prophylactic or therapy |
US7351533B2 (en) * | 1997-09-05 | 2008-04-01 | Medimmune, Inc. | In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents |
US6228368B1 (en) * | 1997-10-06 | 2001-05-08 | Loyola University Of Chicago | Papilloma virus capsomere formulations and method of use |
AU2003200653B2 (en) * | 1997-10-06 | 2007-01-18 | Loyola University Of Chicago | Papilloma virus capsomere vaccine formulations and methods of use |
US20020039584A1 (en) | 1998-02-20 | 2002-04-04 | Medigene Ag | Papilloma virus capsomere vaccine formulations and methods of use |
CA2229955C (en) | 1998-02-20 | 2003-12-09 | Medigene Gmbh | Papilloma virus capsomere vaccine formulations and methods of use |
US7494658B2 (en) * | 1998-02-20 | 2009-02-24 | Medigene Ag | Papilloma virus truncated L1 protein and fusion protein constructs |
US7182947B2 (en) * | 1998-02-20 | 2007-02-27 | Medigene Ag | Papillomavirus truncated L1 protein and fusion protein constructs |
DE19812940A1 (de) * | 1998-03-24 | 1999-10-07 | Medigene Ag | Formulierung mit Papillomavirus-spezifischem Protein, seine Herstellung und Verwendung |
US6926897B1 (en) * | 1998-03-24 | 2005-08-09 | Medigene Aktiengesellschaft | Medicament for the avoidance or treatment of papillomavirus-specific tumour |
GB9806666D0 (en) * | 1998-03-27 | 1998-05-27 | Stanley Margaret | Antigen preparation and use |
AU753391B2 (en) * | 1998-08-14 | 2002-10-17 | Merck Sharp & Dohme Corp. | Protein delivery system using human papillomavirus virus-like particles |
US6991795B1 (en) * | 1998-08-14 | 2006-01-31 | Merck & Co., Inc. | Protein delivery system using human papillomavirus virus-like particles |
EP2266604A3 (en) | 1998-10-16 | 2011-05-11 | GlaxoSmithKline Biologicals S.A. | Adjuvant systems and vaccines |
SE514982C2 (sv) * | 1999-09-30 | 2001-05-28 | Active Biotech Ab | Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning |
DE19925199A1 (de) | 1999-06-01 | 2000-12-07 | Medigene Ag | Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie |
DE19925235A1 (de) | 1999-06-01 | 2000-12-07 | Medigene Ag | Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie |
US20040146531A1 (en) * | 1999-09-30 | 2004-07-29 | Active Biotech Ab | Virus-like particles devoid of HPV 16 type-specific antibody epitopes as carriers of peptides for introduction into cells |
US6908613B2 (en) * | 2000-06-21 | 2005-06-21 | Medimmune, Inc. | Chimeric human papillomavirus (HPV) L1 molecules and uses therefor |
US7279306B2 (en) * | 2000-07-06 | 2007-10-09 | Georgetown University | Stable (fixed) forms of viral capsid proteins, and viral capsid protein fusions, preferably papillomavirus L1 proteins, and uses thereof |
GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
DE10137102A1 (de) * | 2001-07-30 | 2003-02-27 | Deutsches Krebsforsch | Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung |
GB0206360D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
US20060088909A1 (en) * | 2002-05-17 | 2006-04-27 | Compans Richard W | Virus-like particles, methods of preparation, and immunogenic compositions |
JP4614765B2 (ja) * | 2002-05-17 | 2011-01-19 | ユニバーシティ・オブ・ケープ・タウン | L2ペプチドを含むキメラ・ヒト・パピローマウイルス16l1タンパク質、それから調製したウイルス様粒子および該粒子の調製方法 |
US9045727B2 (en) * | 2002-05-17 | 2015-06-02 | Emory University | Virus-like particles, methods of preparation, and immunogenic compositions |
US7858098B2 (en) * | 2002-12-20 | 2010-12-28 | Glaxosmithkline Biologicals, S.A. | Vaccine |
US20080160040A1 (en) * | 2004-04-15 | 2008-07-03 | Ghim Shin-Je | Plant-produced compositions for treating papillomavirus infection and related methods |
US7732166B2 (en) * | 2005-11-15 | 2010-06-08 | Oncohealth Corporation | Detection method for human pappilomavirus (HPV) and its application in cervical cancer |
US7972776B2 (en) * | 2005-11-15 | 2011-07-05 | Oncohealth Corporation | Protein chips for HPV detection |
TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
US8778351B2 (en) | 2006-08-30 | 2014-07-15 | University Of Rochester | Combined human papillomavirus VLP/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors |
CN101148661B (zh) * | 2006-09-18 | 2013-01-02 | 中国医学科学院基础医学研究所 | 人***瘤病毒16型外壳蛋白病毒样颗粒及其制备方法和用途 |
PT2468300T (pt) | 2006-09-26 | 2018-01-30 | Infectious Disease Res Inst | Composição para vacina contendo adjuvante sintético |
US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
US8968995B2 (en) * | 2008-11-12 | 2015-03-03 | Oncohealth Corp. | Detection, screening, and diagnosis of HPV-associated cancers |
US8859218B2 (en) | 2008-06-13 | 2014-10-14 | Oncohealth Corp. | In situ detection of early stages and late stages HPV infection |
WO2008115631A2 (en) * | 2007-02-08 | 2008-09-25 | University Of Louisville Research Foundation, Inc. | Plant-produced compositions for treating papillomavirus infection and related methods |
CN103550764A (zh) | 2007-03-02 | 2014-02-05 | 葛兰素史密丝克莱恩生物有限公司 | 疫苗组合物及其在刺激免疫反应中的用途 |
WO2008134935A1 (fr) | 2007-04-29 | 2008-11-13 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Protéines 18 l1 de type papillomavirus humain tronqué |
DK2154147T3 (en) | 2007-04-29 | 2015-12-07 | Beijing Wantai Biological Pharmacy Entpr Co Ltd | Truncated L1 protein of human papillomavirus 16 |
WO2008145021A1 (en) * | 2007-05-29 | 2008-12-04 | Xiamen University | A truncated l1 protein of human papillomavirus 6 |
CA2703066A1 (en) * | 2007-10-22 | 2009-04-30 | University Of Rochester | Respiratory syncytial virus vaccine based on chimeric papillomavirus virus-like particles or capsomeres |
CN101835797A (zh) * | 2007-11-23 | 2010-09-15 | 上海泽润生物科技有限公司 | 人***状瘤病毒主要衣壳蛋白l1基因及其用途 |
GB0815872D0 (en) | 2008-09-01 | 2008-10-08 | Pasteur Institut | Novel method and compositions |
GB0820822D0 (en) | 2008-11-13 | 2008-12-24 | Inst Catala D Oncologia | Novel product and processes |
CN102449479B (zh) | 2009-05-07 | 2015-11-25 | 安科健康公司 | 鉴别高度或≥cin2用于人***瘤病毒(hpv)与hpv相关癌症的早期及晚期检测、筛检和诊断 |
DK2437753T3 (en) | 2009-06-05 | 2016-12-19 | Infectious Disease Res Inst | Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them |
WO2011084598A1 (en) | 2010-01-08 | 2011-07-14 | Oncohealth Corporation | High throughput cell-based hpv immunoassays for diagnosis and screening of hpv-associated cancers |
CA2832307A1 (en) | 2011-04-08 | 2012-10-18 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
ES2671381T3 (es) * | 2011-06-14 | 2018-06-06 | Globeimmune, Inc. | Composiciones inmunoterapéuticas para el tratamiento o prevención de infección por virus de hepatitis delta |
JP6050811B2 (ja) | 2011-06-24 | 2016-12-21 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | アルミニウムアジュバントを含むhpvワクチン製剤およびその産生方法 |
CA2847604A1 (en) | 2011-09-08 | 2013-03-14 | Uniqure Ip B.V. | Removal of contaminating viruses from aav preparations |
US11510875B2 (en) | 2012-02-07 | 2022-11-29 | Access To Advanced Health Institute | Adjuvant formulations comprising TLR4 agonists and methods of using the same |
EP2827891A1 (en) | 2012-03-18 | 2015-01-28 | GlaxoSmithKline Biologicals S.A. | Method of vaccination against human papillomavirus |
EP2850431B1 (en) | 2012-05-16 | 2018-04-18 | Immune Design Corp. | Vaccines for hsv-2 |
CA2909221A1 (en) | 2013-04-18 | 2014-10-23 | Immune Design Corp. | Gla monotherapy for use in cancer treatment |
US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
CN104231060B (zh) * | 2013-06-05 | 2018-05-15 | 厦门大学 | 人***瘤病毒l1l2衣壳蛋白相互作用位点及其应用 |
KR102411781B1 (ko) | 2013-12-31 | 2022-06-22 | 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) | 단일 바이알 백신 제형 |
IL313085A (en) | 2016-05-16 | 2024-07-01 | Access To Advanced Health Inst | Pegylated liposomes and methods of use |
IL299285A (en) | 2016-05-16 | 2023-02-01 | Access To Advanced Health Inst | Formulation containing a TLR agonist and methods of use |
AU2017273650B2 (en) | 2016-06-01 | 2022-08-18 | Access To Advanced Health Institute | Nanoalum particles containing a sizing agent |
CA3067224A1 (en) | 2017-06-15 | 2018-12-20 | Infectious Disease Research Institute | Nanostructured lipid carriers and stable emulsions and uses thereof |
CN111315406A (zh) | 2017-09-08 | 2020-06-19 | 传染病研究所 | 包括皂苷的脂质体调配物及其使用方法 |
WO2020243115A1 (en) | 2019-05-25 | 2020-12-03 | Infectious Disease Research Institute | Composition and method for spray drying an adjuvant vaccine emulsion |
WO2021013063A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 嵌合的人***瘤病毒16型l1蛋白 |
CN114127099B (zh) * | 2019-07-19 | 2024-04-19 | 神州细胞工程有限公司 | 嵌合的人***瘤病毒6型l1蛋白 |
CN114127097A (zh) * | 2019-07-19 | 2022-03-01 | 神州细胞工程有限公司 | 嵌合的人***瘤病毒56型l1蛋白 |
KR20220074855A (ko) | 2019-07-19 | 2022-06-03 | 사이노셀테크 엘티디. | 인간 유두종바이러스용 다가 면역원성 조성물 |
EP4001297A4 (en) * | 2019-07-19 | 2023-09-27 | Sinocelltech Ltd | CHIMERIC PAPILLOMAVIRUS L1 PROTEIN |
JP2023516904A (ja) | 2020-02-14 | 2023-04-21 | メルク・シャープ・アンド・ドーム・エルエルシー | Hpvワクチン |
US20230310323A1 (en) | 2020-09-04 | 2023-10-05 | Access To Advanced Health Institute | Co-lyophilized rna and nanostructured lipid carrier |
CN114539365B (zh) * | 2020-11-26 | 2023-12-01 | 中国医学科学院基础医学研究所 | 一种改造的人***瘤病毒52型l1蛋白及其用途 |
CN114539363B (zh) * | 2020-11-26 | 2023-12-01 | 中国医学科学院基础医学研究所 | 一种c端改造的人***瘤病毒11型l1蛋白及其用途 |
MX2023009456A (es) | 2021-02-11 | 2023-08-28 | Glaxosmithkline Biologicals Sa | Preparacion de la vacuna contra el vph. |
EP4359010A1 (en) | 2021-06-21 | 2024-05-01 | uniQure biopharma B.V. | Improved lysis procedures |
TW202313658A (zh) | 2021-08-06 | 2023-04-01 | 美商默沙東有限責任公司 | Hpv疫苗 |
WO2023023152A1 (en) | 2021-08-19 | 2023-02-23 | Merck Sharp & Dohme Llc | Thermostable lipid nanoparticle and methods of use thereof |
WO2024052882A1 (en) | 2022-09-09 | 2024-03-14 | Access To Advanced Health Institute | Immunogenic vaccine composition incorporating a saponin |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9113809D0 (en) * | 1991-06-26 | 1991-08-14 | Cancer Res Campaign Tech | Papillomavirus l2 protein |
AU651727B2 (en) * | 1991-07-19 | 1994-07-28 | Csl Limited | Papilloma virus vaccine |
GB9207701D0 (en) | 1992-04-08 | 1992-05-27 | Cancer Res Campaign Tech | Papillomavirus e7 protein |
WO1993020840A1 (en) * | 1992-04-14 | 1993-10-28 | British Bio-Technology Limited | Induction of ctl responses |
DE122007000098I1 (de) | 1992-06-25 | 2008-03-27 | Papillomavirus vakzine | |
US5618536A (en) * | 1992-09-03 | 1997-04-08 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric papillomavirus-like particles |
US5437951A (en) * | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
PT1618888E (pt) * | 1993-03-09 | 2011-04-08 | Univ Rochester | Produção de proteína da cápside de vírus de papiloma humano e partículas semelhantes a vírus |
US6153201A (en) * | 1993-03-09 | 2000-11-28 | University Of Rochester | Oral immunization with papillomavirus virus-like particles |
CA2202090C (en) * | 1994-10-07 | 2012-04-17 | Lutz Gissmann | Papilloma virus-like particles, fusion proteins as well as processes for their production |
WO1996026277A1 (en) * | 1995-02-24 | 1996-08-29 | Cantab Pharmaceuticals Research Limited | Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation |
US5874089A (en) * | 1995-10-02 | 1999-02-23 | Georgetown University School Of Medicine | Protecting against canine oral papillomavirus (copy) |
US6228368B1 (en) * | 1997-10-06 | 2001-05-08 | Loyola University Of Chicago | Papilloma virus capsomere formulations and method of use |
-
1995
- 1995-10-09 CA CA2202090A patent/CA2202090C/en not_active Expired - Lifetime
- 1995-10-09 EP EP06009351A patent/EP1728800A1/de not_active Withdrawn
- 1995-10-09 PT PT95934663T patent/PT809700E/pt unknown
- 1995-10-09 EP EP95934663A patent/EP0809700B1/de not_active Expired - Lifetime
- 1995-10-09 DE DE122007000092C patent/DE122007000092I1/de active Pending
- 1995-10-09 US US08/817,335 patent/US6066324A/en not_active Expired - Lifetime
- 1995-10-09 DE DE59511047T patent/DE59511047D1/de not_active Expired - Lifetime
- 1995-10-09 WO PCT/EP1995/003974 patent/WO1996011272A2/de active IP Right Grant
- 1995-10-09 AU AU42701/96A patent/AU4270196A/en not_active Abandoned
- 1995-10-09 ES ES95934663T patent/ES2264563T3/es not_active Expired - Lifetime
- 1995-10-09 AT AT95934663T patent/ATE325875T1/de active
- 1995-10-09 JP JP8512335A patent/JPH11504801A/ja not_active Withdrawn
- 1995-10-09 DK DK95934663T patent/DK0809700T3/da active
- 1995-10-09 DE DE122007000093C patent/DE122007000093I1/de active Pending
-
1999
- 1999-09-16 US US09/397,680 patent/US6361778B1/en not_active Expired - Lifetime
-
2000
- 2000-01-05 AU AU10106/00A patent/AU760615B2/en not_active Expired
-
2001
- 2001-09-06 US US09/949,404 patent/US6599508B1/en not_active Expired - Lifetime
-
2003
- 2003-07-01 US US10/610,928 patent/US20040202679A1/en not_active Abandoned
-
2005
- 2005-04-27 JP JP2005130613A patent/JP2005270111A/ja not_active Withdrawn
-
2006
- 2006-02-21 US US11/358,474 patent/US7416732B2/en not_active Expired - Fee Related
-
2007
- 2007-12-14 LU LU91401C patent/LU91401I2/fr unknown
- 2007-12-14 NL NL300323C patent/NL300323I2/nl unknown
- 2007-12-14 LU LU91390C patent/LU91390I2/fr unknown
- 2007-12-14 NL NL300324C patent/NL300324I1/nl unknown
-
2008
- 2008-08-25 US US12/197,591 patent/US20110015376A1/en not_active Abandoned
- 2008-11-27 JP JP2008303257A patent/JP2009102327A/ja not_active Withdrawn
-
2011
- 2011-10-04 JP JP2011220539A patent/JP2012010713A/ja not_active Withdrawn
-
2013
- 2013-05-29 JP JP2013112548A patent/JP2013213034A/ja not_active Withdrawn
-
2014
- 2014-11-21 JP JP2014236222A patent/JP5794747B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0809700T3 (da) | Papillomaviruslignende partikler, fusionsproteiner samt fremgangsmåde til fremstilling heraf | |
DE122011100018I1 (de) | Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusahnlichen Teilchen. | |
DE69535018D1 (de) | Papillomavirus vakzine | |
LU91385I2 (fr) | CERVARIX - Particule similaire au virus HPV16 | |
RU93043621A (ru) | Способы получения гликопротеинов нсv, способ очистки, аналитический набор, способ выявления нсv, способ элиминации нсv, способ индукции иммунитета, гликопротеины, иммунореагенты | |
ATE393215T1 (de) | Chimäre virus-ähnliche partikel bzw. chimäre capsomere von bpv (bovine papilloma virus) |